MacroGenics (NASDAQ: MGNX) Q4 2024 Earnings Call Mar 20, 2025, 4:30 p.m. ET ...
Macrogenics Inc (NASDAQ:MGNX) successfully completed the sale of MARGENZA to TerSera Therapeutics, providing non-dilutive capital to invest in their clinical pipeline and R&D efforts. The company ...
In October 2024, MacroGenics completed the sale of its product MARGENZA to TerSera Therapeutics for $40 million, with the potential for an additional $35 million in milestone payments. This move ...
Scotiabank analyst George Farmer lowered the firm’s price target on Tempest Therapeutics (TPST) to $7 from $13 and keeps an Outperform rating ...
In October 2024, MacroGenics completed the sale of its product MARGENZA to TerSera Therapeutics for $40 million, with the potential for an additional $35 million in milestone payments. This move ...
Macrogenics Inc (NASDAQ:MGNX) successfully completed the sale of MARGENZA to TerSera Therapeutics, providing non-dilutive capital to invest in their clinical pipeline and R&D efforts. The company ...
HOPE Therapeutics, wholly owned by NRx Pharmaceuticals (NRXP), announced signing of a binding Letter of Intent, LOI, to acquire a majority ...
Leap to host a conference call to present clinical data today, March 26, 2025, at 8:00 a.m. ET "The updated data from Part B of the DeFianCe study presented today confirms that sirexatamab can ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback